# PDUFA dates June 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-06

> 43 FDA catalysts are dated in June 2027, including 5 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in June 2027?

PDUFA dates in June 2027: ZUSDURI (mitomycin, URGN) on June 14, 2027; Merck & Co., Inc. (MRK) on June 15, 2027; ralinepag (UTHR) on June 24, 2027; Liquidia Corp (LQDA) on June 24, 2027; bezuclastinib (COGT) on June 29, 2027. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-06)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-034769, https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/fda-calendar/2027-06#answer

## PDUFA dates in June 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| June 14, 2027 | UroGen Pharma Ltd. | URGN | ZUSDURI (mitomycin) | with recurrent low-grade intermediate risk NMIBC | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm) |
| June 15, 2027 | Merck & Co., Inc. | MRK |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm) |
| June 24, 2027 | UNITED THERAPEUTICS Corp | UTHR | ralinepag |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm) |
| June 24, 2027 | Liquidia Corp | LQDA |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819576/000110465926124752/lqda-20260930x10q.htm) |
| June 29, 2027 | Cogent Biosciences, Inc. | COGT | bezuclastinib |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm) |

## All catalysts in June 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 2027 | [Fexofenadine (loratadine if not available) primary completion](https://sec-api.dev/pdufa/fexofenadine-loratadine-if-not-available) | SNY | Pruritus | scheduled | "NCT05263206 (Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05263206)) |
| June 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06840392 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06840392)) |
| June 2027 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance | scheduled | "NCT05329649 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05329649)) |
| June 2027 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Asthma | scheduled | "NCT06932263 (Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06932263)) |
| June 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization; Healthy Volunteers | scheduled | "NCT07348692 (Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07348692)) |
| June 2027 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Crohn's Disease | scheduled | "NCT06227910 (A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06227910)) |
| June 2027 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | scheduled | "NCT06408935 (Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06408935)) |
| June 2027 | [Exagamglogene autotemcel primary completion](https://sec-api.dev/pdufa/exagamglogene-autotemcel) | VRTX | Beta-Thalassemia; Thalassemia; Hematologic Diseases | scheduled | "NCT05477563 (Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05477563)) |
| June 2027 | [Cagrisema primary completion](https://sec-api.dev/pdufa/cagrisema) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07817251 (Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817251)) |
| June 2027 | [MK-6916 primary completion](https://sec-api.dev/pdufa/mk-6916) | MRK | Pain Management | scheduled | "NCT07862595 (A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07862595)) |
| June 14, 2027 | [ZUSDURI (mitomycin) PDUFA date](https://sec-api.dev/pdufa/mitomycin) | URGN | with recurrent low-grade intermediate risk NMIBC | scheduled | "The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm)) |
| June 2027 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07266441 (A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266441)) |
| June 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | scheduled | "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07639021)) |
| June 15, 2027 | [Merck & Co., Inc. PDUFA date](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | scheduled | "FDA set Prescription Drug User Fee Act (PDUFA) date of June 15, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm)) |
| June 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight | scheduled | "NCT07871409 (Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-16 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871409)) |
| June 2027 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Monogenic Obesity | scheduled | "NCT07220772 (A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220772)) |
| June 2027 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | scheduled | "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06676319)) |
| June 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT06690398 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06690398)) |
| June 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT06706674 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706674)) |
| June 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | PIK3CA-related Overgrowth Spectrum (PROS) | scheduled | "NCT04980833 (Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980833)) |
| June 2027 | [Vaccine candidate #1 primary completion](https://sec-api.dev/pdufa/vaccine-candidate-1) | PFE | Healthy Adults | scheduled | "NCT07431853 (A Study to Learn About mRNA Vaccines Against Influenza in Adults): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431853)) |
| June 24, 2027 | [Ralinepag PDUFA date](https://sec-api.dev/pdufa/ralinepag) | UTHR |  | scheduled | "In August 2026, we were notified that the FDA had accepted our NDA and established a user fee goal date of June 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm)) |
| June 24, 2027 | [Liquidia Corp PDUFA date](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | scheduled | "In August 2026, the FDA accepted the NDA for ralinepag to treat PAH and set a PDUFA target action date of June 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819576/000110465926124752/lqda-20260930x10q.htm)) |
| June 2027 | [Belsomra (suvorexant) primary completion](https://sec-api.dev/pdufa/suvorexant) | MRK | Insomnia | scheduled | "NCT06655883 (A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655883)) |
| June 2027 | [Symbicort Aerosphere (budesonide; formoterol fumarate) primary completion](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN | Severe Asthma | scheduled | "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06473779)) |
| June 2027 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Mania; Bipolar Disorder | scheduled | "NCT07140913 (A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07140913)) |
| June 2027 | [JNJ-88545223 primary completion](https://sec-api.dev/pdufa/jnj-88545223) | JNJ | Arthritis, Psoriatic | scheduled | "NCT07321873 (A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321873)) |
| June 29, 2027 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Potential FDA approval of bezuclastinib in AdvSM - PDUFA date of June 29, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| June 30, 2027 | [Bemnifosbuvir NDA/BLA submission](https://sec-api.dev/pdufa/bemnifosbuvir) | AVIR |  | scheduled | "If we successfully complete the ongoing HCV Phase 3 clinical trials evaluating the regimen of bemnifosbuvir and ruzasvir and are able to complete and submit the NDA to the FDA on our current projected timeline, we anticipate that this next potential milestone may become due and payable during the three months ended June 30, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1593899/000119312526219678/avir-20260331.htm)) |
| June 30, 2027 | [CYB003 topline data readout](https://sec-api.dev/pdufa/cyb003) | HELP |  | scheduled | "Each Warrant will be exercisable to acquire one Common Share at a price of US$8.14 per Common Share at any time prior to the earlier of: (i) June 30, 2027; (ii) thirty days following the publication by press release of topline data for the APPROACH trial of CYB003 in major depressive disorder; and (iii) thirty days following the date a press release is issued by the Company announcing exercise of its acceleration right, which right can only be exercised if the closing price of the Common Share on NYSE American LLC (the "NYSE American") is equal to or exceeds US$19.53 per Common Share for any five consecutive trading days." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1833141/000183314125000046/materialchangereportcybin-.htm)) |
| June 2027 | [Nano2tm primary completion](https://sec-api.dev/pdufa/nano2tm) | NUOX | Glioblastoma Multiforme | scheduled | "NCT03862430 (A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor NuvOx LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03862430)) |
| June 2027 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Urothelial Carcinoma | scheduled | "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03967977)) |
| June 2027 | [Etelcalcetide primary completion](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism | scheduled | "NCT03969329 (A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03969329)) |
| June 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Esophageal Squamous Cell Carcinoma | scheduled | "NCT04550260 (Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04550260)) |
| June 2027 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Hematological Malignancies | scheduled | "NCT04634552 (A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634552)) |
| June 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT05265273 (A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05265273)) |
| June 2027 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05920356)) |
| June 2027 | [Tinlarebant primary completion](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Geographic Atrophy | scheduled | "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949593)) |
| June 2027 | [Olverembatinib primary completion](https://sec-api.dev/pdufa/olverembatinib) | AAPG | Chronic Myeloid Leukemia; CML; CML, Chronic Phase | scheduled | "NCT06423911 (Study of Olverembatinib (HQP1351) in Patients With CML-CP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06423911)) |
| June 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Colorectal Cancer | scheduled | "NCT06792695 (A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06792695)) |
| June 2027 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT07200908 (A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07200908)) |
| June 2027 | [Exaluren primary completion](https://sec-api.dev/pdufa/exaluren) | ELOX | Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive | scheduled | "NCT07523581 (EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Eloxx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07523581)) |
| June 2027 | [ALN-6400 primary completion](https://sec-api.dev/pdufa/aln-6400) | ALNY | Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) | scheduled | "NCT07575308 (HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575308)) |

Other months: https://sec-api.dev/fda-calendar/2027-05 , https://sec-api.dev/fda-calendar/2027-07. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates June 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-06

```bibtex
@misc{secapidev_fda_calendar_2027_06_20261116,
  title        = {PDUFA dates June 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-06}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_06_20261116","title":"PDUFA dates June 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-06","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
